Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study. (August 2021)

• Record Type: Journal Article
• Authors: Rudofsky, Gottfried; Catarig, Andrei-Mircea; Favre, Lucie; Grau, Katrine; Häfliger, Susan; Thomann, Robert; Schultes, Bernd
• Is Part Of: Diabetes research and clinical practice. Volume 178(2021)
• Publication Date: 2021-08
• Subjects: SURE study -- Glucagon-like peptide-1 receptor agonist -- Glucose control -- Real-world evidence -- Semaglutide -- Type 2 diabetes; Diabetes -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462
• DOI: 10.1016/j.diabres.2021.108931
• Languages: English
• ISSNs: 0168-8227

Abstract

Highlights: The SURE programme was conducted to complement the SUSTAIN clinical trial programme. SURE Switzerland studied real-world once-weekly semaglutide use in adults with T2D. Patients experienced significant HbA1c and body weight reductions. No new safety signals were identified. This supports once-weekly semaglutide clinical use in Switzerland in adults with T2D. Abstract: Aims: SURE Switzerland (NCT03631186) investigated real-world once-weekly (OW) semaglutide use in adults with type 2 diabetes (T2D). Methods: This multicentre, prospective, observational study enrolled adults with T2D with ≥ 1 documented HbA1c value ≤ 12 weeks before semaglutide initiation. Primary endpoint was change in HbA1c from baseline to end of study (EOS; ~30 weeks). Secondary endpoints included changes in body weight (BW) and waist circumference (WC), and the proportion of patients achieving HbA1c < 8.0%, <7.5% and <7.0% at EOS. Semaglutide dose at EOS was a prespecified exploratory endpoint. Results: Overall, 214 patients initiated semaglutide (baseline HbA1c 7.8% [62 mmol/mol], BW 99.9 kg and WC 117.4 cm); 187 attended the EOS visit. At EOS, 175 (81.8%) were still receiving semaglutide (mean [SD] dose 0.78 [0.29] mg); in those patients, mean HbA1c reduced by −0.8 [95% CI − 1.01;−0.68] %-points (−9 [−11;−7] mmol/mol), BW by −5.0 kg [−5.73;−4.24] and WC by −4.8 cm [−5.75;−3.79] (all p < 0.0001). At EOS, 85.9%, 76.5% and 55.9% patients achieved, respectively, HbA1c < 8.0%, <7.5% and < 7.0%. No new safety signals were identified. Conclusions: Patients with T2D in Switzerland initiating OW semaglutide experienced clinically relevant glycaemic control and BW improvements in a real-world setting, supporting semaglutide use in routine clinical practice.